ASPirin in Immune thRombocytopenia Patients With Cardiovascular disEase

• Status: Not yet recruiting
• Trial end date: 2023-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The incidence of immune thrombocytopenia increases with older age. This population is at risk for arterial thrombosis. Due to an increased turn-over of platelets, low-dose aspirin once daily may be insufficient in this population to protect against arterial thrombosis. This study is aimed at assessing the pharmacodynamics of aspirin once daily on platelet function in these patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Toulouse
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• adult patients

• non-treated immune thrombocytopenia or immune thrombocytopenia with stable treatment (at least 1 month)

• treated with aspirin daily for a cardiovascular disease; stable platelet count < 100 x 109/L

• at least one month following an arterial thrombosis

• no other antiplatelet drug and anticoagulant

• female patient with childbearing potential must have acceptable method of birth control

• affiliated or benefiting from public health insurance

Exclusion Criteria:

• opposition to participate

• adults under guardianship or other legal protection

• deprived of their liberty by judicial or administrative decision

• pregnancy or breastfeeding